IDEAS home Printed from
   My bibliography  Save this paper

Multi-indication Pricing: Pros, Cons and Applicability to the UK


  • Mestre-Ferrandiz, J.
  • Towse, A.
  • Dellamano, R.
  • Pistollato, M.


Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent medicines are to reflect their value, then multi-indication medicines should have different prices across major indication, reflecting different values. A workshop with health care system stakeholders was organised to explore (i) the attractiveness of MIP as a potential solution to the challenge of providing optimal pricing for, and reimbursement of, multi-indication drugs and (ii) the feasibility of implementing MIP in the UK's National Health Service (NHS). The workshop agreed that relative prices should reflect relative value, with prices for any indication not exceeding value, and thus MIP could be a way forward. However, a number of operational challenges need to be overcome. This OHE Briefing contains a summary of the main points discussed at the workshop, together with a summary of the briefing material provided to the participants.

Suggested Citation

  • Mestre-Ferrandiz, J. & Towse, A. & Dellamano, R. & Pistollato, M., 2015. "Multi-indication Pricing: Pros, Cons and Applicability to the UK," Seminar Briefings 001653, Office of Health Economics.
  • Handle: RePEc:ohe:sembri:001653

    Download full text from publisher

    File URL:
    Download Restriction: no

    References listed on IDEAS

    1. Jean Tirole, 1988. "The Theory of Industrial Organization," MIT Press Books, The MIT Press, edition 1, volume 1, number 0262200716, January.
    2. Rejon-Parrilla, J.C & Hernandez-Villafuerte, K. & Shah, K. & Mestre-Ferrandiz, J. & Garrison, L. & Towse, A., 2014. "The Expanding Value Footprint of Oncology Treatments," Consulting Reports 000050, Office of Health Economics.
    3. Chapman, A. & Karlsberg Schaffer, S., 2015. "Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK," Consulting Reports 001595, Office of Health Economics.
    4. Danzon, Patricia M. & Chao, Li-Wei, 2000. "Cross-national price differences for pharmaceuticals: how large, and why?," Journal of Health Economics, Elsevier, vol. 19(2), pages 159-195, March.
    Full references (including those not matched with items on IDEAS)


    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.

    Cited by:

    1. Towse, A. & Cole, A. & Zamora, B., 2018. "The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries," Consulting Reports 002009, Office of Health Economics.

    More about this item


    Economics of Industry;

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:sembri:001653. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Publications Manager). General contact details of provider: .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.